Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
about
Tamsulosin for benign prostatic hyperplasiaTamsulosin for benign prostatic hyperplasia.Emerging drug therapies for benign prostatic hyperplasia.Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.Measurement of benign prostatic hyperplasia treatment effects on male sexual function.Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients.Alpha-blocker test: alternative to pressure-flow study of bladder outlet obstruction and detrusor contractility in patients without an enlarged prostate.Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score.Seasonal changes in symptom score and uroflowmetry in patients with lower urinary tract symptoms.
P2860
Q24234556-8CBBF17E-48DB-4048-B7B9-9BF3C709756DQ30882035-7B5DEAE4-F27D-422C-9D9F-BE2258229F1AQ34565171-B1BE9417-0A5C-4663-ABF3-2FB66C877CDDQ35204840-7FC39417-2516-4946-8138-01741C97E13AQ35855002-B1EDB8A0-CCBF-4031-AD94-CC6FA8A087DBQ36371582-49CCD87A-A278-4DD6-874B-62D55CDE41DFQ36737065-E4099D42-F5FA-477A-99EB-66C369851FBBQ37523227-A96F2649-D44F-4100-BA7E-0AC4CFE313D9Q38093143-714DF40A-C02C-4C88-80F8-FE460C614DA9Q38364582-2AF8202F-8153-4F1E-9F42-8F4C51092D1AQ39355168-C77D5075-13C7-46BD-BCC4-B3277D20A643Q39375083-A1763E00-F0E6-40F1-AF1E-06D3A74E8DBCQ44277081-499475FD-F93E-46B0-A4A0-C8F7D3F26947Q44695184-5E7CBDE3-72A7-4815-AA27-40FE68A64E07Q51912453-45FD6786-3C46-4E7F-9B10-3EFDD04E7F01Q53153772-1FB1D9C4-5C25-4401-842C-1B0BD7FE4CCFQ53176615-8BAE9B0C-3441-4D17-A15D-95A8CABACD76
P2860
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@en
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@nl
type
label
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@en
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@nl
prefLabel
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@en
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@nl
P2093
P356
P1433
P1476
Tamsulosin: 3-year long-term e ...... ropean Tamsulosin Study Group.
@en
P2093
P304
P356
10.1159/000020056
P407
P577
1999-12-01T00:00:00Z